This study was a phase II evaluation of the activity of carboplatin in patients with Philadelphia chromosome positive accelerated or blastic phase of CML. Carboplatin, 250 mg/m 2 /day as an intravenous continuous infusion was given for 5 days, for a total dose of 1250 mg/m 2 per course. If necessary, a second induction course could be given, and patients achieving complete remission were to receive an additional consolidation cycle at the same dose. Thirty-six patients were eligible and evaluable. There were five complete and three partial remissions for an overall response rate of 22% (95% CI 10.1-39.1%). The complete remission rate was 13.9% (95% CI 4.7-29.9%). The median remission duration was 3 months (range 1.4-8.94 months) and the median survival on study for all patients was 3.5 months (95% CI, 2.4-11.4 months). The median survival of responders was 12.8 months (95% CI, 3.6-17.2 months). Three eligible patients survived 2.0, 2.5 and 3.5 years following carboplatin therapy. Carboplatin has activity in blast crisis of CML, but responses are brief. Response did allow one patient to proceed to bone marrow transplantation and two other patients to continue therapy for chronic phase disease before returning to blast crisis. Activity in combination regimens should be explored.
Introduction
Blast crisis of chronic myeloid leukemia (CML-BC) is a disease highly resistant to chemotherapy. Clinical trials of various regimens over the past two decades have failed to improve response rate, response duration or survival. [1] [2] [3] In more recent times, occasional patients who do return to chronic phase with chemotherapy regimens have been able to successfully undergo bone marrow transplantation, and thus achieve some improvement in survival. Clearly, new anti-leukemic agents are needed for this disease.
Carboplatin (diamine(1,1-cyclobutanedi-carboxylato(2-)-0,0)platinum) is a second generation platinum complex, a cyclobutane dicarboxylate derivative of cisplatin. The mechanism of cytotoxicity is through its binding to replicating DNA which alters the superhelical conformation of the DNA and induces single strand breaks. Carboplatin has demonstrated activity in a number of solid tumors, including ovarian and lung cancer and is now widely utilized. 4, 5 Carboplatin does not produce the nephrotoxicity of cisplatin, and is associated with less neurotoxicity than cisplatin. Its major toxicity is myelosuppression, unlike cisplatin. Because of this toxicity, there has been interest in evaluating this agent in the hematologic malignancies.
Several studies of carboplatin have been performed in acute myeloid leukemia. Lee (AML) treated with daily intravenous bolus carboplatin at escalating doses. However, Meyers et al 7 reported that when the schedule was changed to intravenous continuous infusion over 5 days, 7/27 patients achieved complete remission (CR) and two achieved partial remission (PR) for a response rate of 30% in relapsed/refractory AML. One patient with CMLBC also achieved a CR. 7 Vogler et al 8 reported similar results in AML patients in an Eastern Cooperative Oncology Group (ECOG) study using a continuous infusion schedule.
Based on these preliminary findings and the response noted in a patient with CMLBC, this phase II study of continuous infusion carboplatin was initiated, and the patient population was restricted to blast crisis or clearly accelerating CML.
Patients and methods

Patients
Thirty-eight patients were entered on to this study, but one was a duplicate registration, and one was ineligible due to failure of registration in the required correlative leukemia biology study. Therefore, 36 patients were deemed eligible and evaluable. The median age was 54 years with a range of 31-74 years, which is typical of chemotherapy trials in this stage of CMl. [1] [2] [3] Characteristics of these 36 patients are presented in Tables 1 and 2 , and these are similar to those of patients entered into previous clinical trials of therapy in CMLBC. [1] [2] [3] Five patients had no prior therapy for chronic phase of CML, three because they presented in blastic phase, and two who were stable for 5 and 6 years prior to blastic phase. The other 31 patients were heavily previously treated, often with multiple treatments, including hydroxyurea (28 patients), alpha interferon (11 patients), busulfan (11 patients), radiation (three patients), anagrelide (two patients), and 6-thioguanine (one patient). Three patients had received prior vincristine and prednisone. The median time to development of accelerated or blastic phase was 3.5 years (range 0-13 years), 6 months longer than reported in earlier trials of blastic CML, perhaps reflecting modern treatment during chronic phase.
Patient samples were required to undergo cytogenetic and immunophenotypic analysis (entry into ECOG study 1485). The protocol was approved by the institutional review boards of all participating institutions. All patients gave written informed consent.
Treatment course
The treatment regimen consisted of a continuous intravenous infusion of carboplatin at 250 mg/m 2 /day for 5 days for a total dose of 1250 mg/m 2 per course. Patients then underwent marrow evaluation at day 14, and if still hypercellular, a second course could be initiated at that time. A second course could be started subsequently if a regenerating marrow revealed incomplete response. Patients failing two induction courses were removed from study and patients achieving remission were to receive one course of consolidation therapy at the same dose and schedule.
Response assessment
Complete response (CR) was defined as normalization of white blood cell count and platelet count and no blasts in the peripheral blood, with response continuing at least 4 weeks. Criteria for CR by bone marrow status included cellularity of greater than 20%, with maturation of all cell lines and with less than 5% blasts. Partial response required normalization of peripheral blood, but with 5-25% blasts in the marrow.
Statistical analysis
The primary endpoint for this study was the complete response rate, and the study utilized the two-stage design of Simon 9 to allow for early termination if the treatment demonstrated insufficient benefit. This study proceeded to stage II. Overall response rate, survival and toxicity were also evaluated. Associations between categorical variables and response were assessed by a Fisher's exact test and significance of variables predicting response was also tested using logistic regression. 10 Estimates of survival utilized the methods of Kaplan and Meier, 11 and significance of a difference between survival curves was evaluated using the log-rank test. 12 All P values reported are based on two-sided significance tests.
Results
Treatment course
Twenty-two patients received two induction courses of carboplatin and four received a consolidation course of carboplatin after returning to chronic phase. Four patients were subsequently maintained on hydroxyurea or busulfan after two induction courses. Of the eight responders, three received three cycles and five received two cycles of carboplatin. One stable patient received three cycles. Twelve patients had only one induction course, due to death from aplasia (eight patients) and rapid progression (four patients).
Clinical outcome
Among the 36 evaluable patients, five achieved CR and three achieved PR, defined using both marrow and peripheral blood evaluation, for an overall response rate of 22.2% (95% CI, 10.1-39.1%) and complete response rate of 13.9% (95% CI, 4.7-29.9%). Median CR duration was 3 months (range 1.4-9 months) and median PR duration was 2.7 months (range 1.4-4 months). Clinical and biological characteristics of the responders are described below and shown in Table 3 .
The median overall survival on study was 3.5 months (95% CI, 2.4-11.4 months). The median survival of responders was 12.8 months (95% CI, 3.6-17.2 months). Three eligible patients had prolonged survival after carboplatin of 2.0, 2.5 and 3.5 years, one of whom achieved CR and successfully underwent bone marrow transplantation. A fourth patient (the ineligible patient due to failure of registration) also survived 2 years after carboplatin therapy treated according to protocol. Characteristics that predicted for survival included age less than 54.5 years (P = 0.04) and those with lower blast counts (less than 33%) (P = 0.02). Characteristics of the responders (Table 3) The responders, five CR and three PR, consisted of three females and five males, with a median age of 50 years (range, 43-71 years). The median time to development of blast crisis was 3.25 years (range, 4 months to 13 years). The median percentage of peripheral blood blasts was less than 36%. Of the eight responders, one was a patient with lymphoid blast crisis (achieved CR) and the other CR and PR patients all had myeloid blast crisis. Two patients had poor marrow specimens that did not yield cytogenetic analysis. For the six responders who could undergo cytogenetic studies, there were three whose only abnormality was a single Philadelphia chromosome. The other three all had a Ph chromosome plus Characteristics of the long-term survivors Four patients (one deemed ineligible) were long-term survivors (2.0, 2.0, 2.5 and 3.5 years) after completing protocol treatment with carboplatin for blastic phase of CML, only one of whom achieved a CR with carboplatin. The other three had major antileukemic effects, stabilized their disease status and became more responsive to previously ineffective agents. The patient achieving CR remained in remission for 9 months, relapsed, and was retreated with vincristine and prednisone and survived 22 months after carboplatin. The second patient received two induction courses, with a major antileukemic effect and stabilization of peripheral blood counts and marrow blasts and had a markedly hypocellular marrow. He then underwent bone marrow transplantation and remained in CR for 3.5 years until blast crisis recurred. The third patient became aplastic after one cycle of carboplatin, but had residual blasts. This patient remained in a 'smouldering' state, later described as chronic phase, on busulfan, for 2.5 years, when blast crisis returned. Finally, the ineligible patient, who was treated according to protocol, had a major antileukemic effect with three cycles of carboplatin, achieved stabilization of peripheral blood counts and marrow status, but without a reduction in splenomegaly. This patient was then maintained on hydroxyurea and intermittent cytarabine for 2 years until death from a cerebrovascular accident.
Toxicity
The toxicities observed were consistent with the stage of the disease and the intensity of the therapy. There were no unexpected toxicities or events observed. The majority of patients developed grade 4 hematologic toxicity including 32 (89%) with leukopenia and 35 (97%) with thrombocytopenia. Grade 4 non-hematologic toxicity included infection (one patient), hepatic toxicity (six patients), cardiac event (one patient), cutaneous toxicity (one patient) and other metabolic toxicities in two patients with renal failure. There were seven deaths on study, six within the first 30 days. Two were from hemorrhage on days 24 and 27; two were from renal failure associated with sepsis on days 13 and 15; two were from infection on days 21 and 273 (never having recovered hematopoietic function) and one was from pulmonary edema on day 27, thought to be caused by a cardiac event. The treatment-related mortality and morbidity is comparable to that seen in other studies of treatment during blastic phase of CML.
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Conclusions
In this phase II study, carboplatin showed activity against CMLBC at a level similar to that reported for this drug as a single agent in patients with relapsed AML. 7, 8 The major toxicities were related to the complications of pancytopenia, whether disease or drug related. As in other studies of CMLBC, prolonged pancytopenia was also seen as a feature of both the disease and its treatment. The median survival on study of responders was greater than that of the entire group (12.8 vs 3.5 months) and three additional patients who did not meet response criteria, nevertheless had a stabilization of disease activity with prolonged survival before redevelopment of blast crisis.
In view of the very limited armamentarium available for patients with blast crisis of CML, it is our interpretation that carboplatin should be further evaluated in combination with other agents. Agents or regimens used in CMLBC which can reinduce the chronic phase of CML have potential when the overall therapeutic plan includes transplantation upon achieving CR. Provided such a plan can be prospectively established in treating patients with blast crisis, there is potential for benefit with chemotherapy regimens for treatment of CMLBC. At the Albert Einstein Cancer Center, preliminary data suggest enhanced activity in the treatment of CMLBC with the combination of carboplatin and mitoxantrone, another single agent with activity in CMLBC. 13 This regimen is currently being evaluated in larger numbers of patients.
